Synergistic composition of quinazolinone compounds with rifampicin to potentiate efficacy against m. tuberculosis

IN607083BActive Publication Date: 2026-10-26COUNCIL OF SCI & IND RES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202111054718
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-11-26
Publication Date
2026-10-26
Estimated Expiration
2041-11-26

AI Technical Summary

Technical Problem

Mycobacterium tuberculosis resistance to first-line TB drugs, particularly rifampicin, is a significant challenge due to over-expression of efflux pumps, which existing treatments fail to effectively address, leading to multi-drug resistant and extensively drug-resistant TB strains.

Method used

A synergistic composition of quinazolinone compounds, specifically 11H-Pyrido[2,1-b]quinazolin-11-one derivatives, is used in combination with rifampicin to inhibit efflux pumps, reducing the minimum inhibitory concentration (MIC) of rifampicin and enhancing its bactericidal activity against M. tuberculosis.

Benefits of technology

The combination of quinazolinone compounds with rifampicin significantly reduces the MIC of rifampicin, demonstrating synergistic bactericidal activity and inhibiting efflux pump expression, thereby overcoming drug resistance in M. tuberculosis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a synergistic composition to potentiate the efficacy of rifampicin against Mycobacterium tuberculosis comprising:(a)a quinazolinone compounds of Formula I wherein Rl is selected from the group consisting of H, Br, CI and F and R2 is selected from the group consisting of H, CI, F and Me and (c) rifampicin, wherein the ratio of compounds of Formula I to rifampicin is 1:0.007 The present invention also demonstrates the synergistic properties and cytotoxicity assay of the lli7-pyrido[2,l-&]quinazolin-ll-onecompounds that also demonstrates the ability to inhibit intracellular growth of M. tuberculosis. The compounds showed excellent properties to reduce the expression of rifampicin efflux pumps.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTIONThe present invention relates to a synergistic composition of a rifampicin efflux pump inhibitor in Mycobacterium tuberculosis with rifampicin. The present invention particularly relates to a synergistic composition of quinazolinone compounds with rifampicin to potentiate efficacy against M. tuberculosis. The present invention more particularly relates to a synergistic composition of quinazolinone compounds as rifampicin efflux pump inhibitor in M. tuberculosis.BACKGROUND OF THE INVENTIONMycobacterium tuberculosis is an etiological agent of tuberculosis (TB), which is responsible for more than 2million deaths per annum worldwide (cf. World Health Organization X. Global tuberculosis report. 2016). The WHO global report showed 460,000 patients suffering from multi-drug resistant TB (MDR-TB) of which 16% died, 8000 patients were reported to have extensive-drug resistant TB (XDR-TB) and 6.2% of people suffering from MDR-TB have XDR-TB (cf. World Health Organization X. Global tuberculosis report. 2016). WHO have placed countries like Brazil, India, China, Bangladesh, Indonesia in the top 30 high TB burden countries (cf. World Health O. Road map for zoonotic tuberculosis. 2017). M. tuberculosis resistant to the firstline TB-drugs are responsible for MDR TB. When the MDR organism become resistant to any fluoroquinolones, and one of the three aminoglycoside antibiotics it is responsible for XDR-TB (cf. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, Van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet. 2010). Unlike most of the resistant microorganism M. tuberculosis show spontaneous mutation to survive antibiotic stress instead of horizontal transfer of resistance genes (cf. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis:1998 update. Tubercle and Lung disease. 1998).In most of the clinical cases, mutation fails to explain the drug resistance phenomenon (cf. Louw G, Warren R, van Pittius NG, McEvoy C, Van Helden P, Victor T. A balancing act: efflux / influx in mycobacterial drug resistance. Antimicrobial agents and chemotherapy. 2009). In such cases the prevailing explanation is the over-expression of efflux pump (cf. EscribanoI, Rodriguez J, Llorca B, Garcia-Pachon E, Ruiz M, Royo G. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy. 2007) (cf. Spies FS, Da Silva PEA, Ribeiro MO, Rossetti ML, Zaha A. Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrobial agents and chemotherapy. 2008). Hence, understanding of efflux pump mechanism and exploration of efflux pump inhibitors (EPIs) is the most direct approach for eradicating the rapidly growing resistance problem.A correlation between upshot of drug resistance in M. tuberculosis and over expression of efflux pumps, especially in clinical isolates, has been investigated (cf. Louw, G.; Warren, R.; van Pittius, N. G.; McEvoy, C.; VanHelden, P.; Victor, T., A balancing act: efflux / influx in mycobacterial drug resistance. Antimicrobial agents and chemotherapy. 2009) (cf. Spies, F.S.; DaSilva, P.E.A.; Ribeiro, M.O.; Rossetti, M.L.; Zaha, A., Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrobial agents and chemotherapy2008). Thus, inhibition of such drug extruding proteins with the help of efflux pump inhibitors is one of themost feasible way to control the resistance problem.11-H-Pyrido[2,1-b]quinazolin-11-one(Quinazolinone),an important class of nitrogen containing heterocycles, constitute the central core unit of a various natural products and pharmaceutically active molecules (cf. Zhuang Y, Teng X, Wang Y, Liu P, Li G, Zhu W. New quinazolinone alkaloids within rare amino acid residue from coral-associated fungus, Aspergillus versicolor LCJ-5-4. Organic letters.2011) (cf. Khan I, Ibrar A, Ahmed W, Saeed A Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: the advances continue. European journal of medicinal chemistry. 2015) with various biological activities including anticancer, antimalarial (cf. Khan I, Ibrar A, Ahmed W, Saeed A. Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: the advances continue. European journal of medicinal chemistry 2015), anti-hypertensive, anti-inflammatory (cf. Alagarsamy V, Solomon VR, Dhanabal K. Synthesis and pharmacological evaluation of some 3-phenyl-2-substituted-3H-quinazolin-4one as analgesic, anti-inflammatory agents. Bioorganic & medicinal chemistry. 2007), and anti-tuberculosis activities (cf. Nandy P, Vishalakshi M, Bhat A. Synthesis and antitubercular activity of Mannich bases of 2-methyl-3H-quinazolin-4-ones. Indian Journal of heterocyclic chemistry. 2006). Now-a-days, they have been frequently used in medicine (cf. Xia Y, Yang Z-Y, Hour M-J, Kuo S-C, Xia P, Bastow KF, et al. Antitumor agents. Part 204: 1 synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorganic& medicinal chemistry letters) e.g., Quinethazone and Metolazone are used as diuretics, while Prazosin is used as vasodilator. EPI behavior of alkyl amino quinazoline in Enterobacter aerogenes with over expressed efflux pumps have been reported. Quinazolinone derivatives were found to restore antibiotic activity of chloramphenicol and norfloxacin in various Gram-negative clinical isolate (cf. Mahamoud A, Chevalier J, Baitiche M, Adam E, Pages J-M. An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates. Microbiology. 2011). In presence of quinazolinone analogues effective over time accumulation of norfloxacin and EtBr in M. smegmatis was observed, thus confirming their role as efflux pump inhibitor (cf. Sen, T., Neog, K., Sarma, S., Manna, P., DekaBoruah, H.P., Gogoi, P., Singh, A.K., Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in Mycobacteria, Bioorganic & Medicinal Chemistry. 2018).OBJECTIVES OF THE INVENTION The main objective of the present invention is to provide a synergistic composition of a rifampicin efflux pump inhibitor in M. tuberculosis with rifampicin to potentiate efficacy against M. tuberculosis. Another objective of the claimed invention is to provide a synergistic composition of quinazolinone compounds and rifampicin to potentiate efficacy against M. tuberculosis. SUMMARY OF INVENTIONAccordingly, the present invention provides a synergistic composition to potentiate the efficacy of rifampicin against M. tuberculosis comprising:a. a quinazolinone compound of Formula IWhere in R1 is selected from the group consisting of H, Br, Cl and F and R2 is selected from the group consisting of H, Cl, F and Me andb. rifampicin, wherein the ratio of compounds of Formula I to rifampicin is 1:0.007In an embodiment of the present invention the compound of Formula I is selected from the group consisting of:11H-Pyrido[2,1-b]quinazolin-11-one,6-Methyl-11H-pyrido[2,1-b]quinazolin-11-one,6,8-Difluoro-11H-pyrido[2,1-b]quinazolin-11-one,2-Bromo-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one, 2-Bromo-7-methyl-11H-pyrido[2,1-b]quinazolin-11-one,3-Bromo-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one,3-Chloro-11H-pyrido[2,1-b]quinazolin-11-one,3-Fluoro-11H-pyrido[2,1-b]quinazolin-11-one,4-Chloro-11H-pyrido[2,1-b]quinazolin-11-one, 4-Chloro-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one,4-Chloro-7-methyl-11H-pyrido[2,1-b]quinazolin-11-one,4,6-Dichloro-11H-pyrido[2,1-b]quinazolin-11-one,4-Chloro-8-fluoro-11H-pyrido[2,1-b]quinazolin-11-one,12-Chloro-8H-isoquinolino[1,2-b]quinazolin-8-one, 4-Fluoro-11H-pyrido[2,1-b]quinazolin-11-one and4-Fluoro-7-methyl-11H-pyrido[2,1-b] quinazolin-11-one.In an embodiment of the present invention, in the compound of formula, R1 is selected from Br and F and R2 is Me.In an embodiment of the present invention, the compound of Formula I is 3-Bromo-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one.In another embodiment of the present invention, the compounds of Formula I is 4-Fluoro-7-methyl-11H-pyrido[2,1-b]quinazolin-11-one.In another embodiment of the claimed invention the composition is in the form of an oral suspension, capsule or tablet with excipients selected from the group consisting of methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, potassium sorbate, sodium metabisulphite, tween 80, diethanolamine, purified water, magnesium stearate, erytrosine, indigotine, sodium formaldehyde sulfoxylate, Ascorbic Acid, lactose monohydrate, talc, magnesium stearate, calcium stearate, lactose, titanium dioxide, iron oxide red, iron oxide yellow, iron oxide black, gelatin, shellac glaze, propylene glycol and ammonium hydroxide.In yet another embodiment of the present invention, the compounds of Formula I acts as a rifampicin efflux pump inhibit or in M. tuberculosis.In an embodiment of the present invention, in the MIC of rifampicin is reduced by 8-folds in the presence of compound of formula 1.In another embodiment of the present invention, the synergistic bactericidal activity is exhibited within 48 h to 72 h. The present invention provides a process for preparing a synergistic composition to potentiate the efficacy of rifampicin against M. tuberculosis comprising mixing;(a) a quinazolinone compounds of Formula Iwherein R1 is selected from the group consisting of H, Br, Cl and F and R2 is selected from the group consisting of H, Cl, F and Me and(b) rifampicin,at a ratio of 1:0.007An embodiment of the present invention also provides a process for the preparation of quinazolinone compounds of Formula I. BRIEF DESCRIPTION OF THE DRAWINGSFigure 1 illustrates Cytotoxicity assay of 3f and 3p on THP-1 macrophages.Figure 2 displays the efficacy of 3f in combination with rifampicin on Mtb H37Rv infected macrophagesFigure 3 displays the efficacy of 3p in combination with rifampicin on Mtb H37Rv infectedmacrophagesFigure4 displays the differential expression of efflux pump genes on treatment withRifampicin (4 μg / ml) + 3f (6.25 μg / ml) and Rifampicin (4 μg / ml) +3p (6.25 μg / ml)Figure 5 displays the differential expression of efflux pump genes on treatment withRifampicin (16 μg / ml) + 3f (6.25 μg / ml) and Rifampicin (16 μg / ml) + 3p (6.25 μg / ml)DETAILED DESCRIPTION OF THE INVENTIONThe present invention provides a synergistic composition to potentiate the efficacy of rifampicinagainst M. tuberculosis comprising:a. a quinazolinone compounds of Formula Iwherein R1 is selected from the group consisting of H, Br, Cl and F and R2 is selected fromthe group consisting of H, Cl, F and Me andb. rifampicin, wherein the ratio of compounds of Formula I to rifampicin is 1:0.007The quinazolinone compounds of Formula I are selected fromGeneral procedure for the synthesis of quinazolinone derivatives from 2-aminopyridineand 2-fluorobenzonitrileAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-aminopyridine (1 mmol, 1 euiv), 2-fluorobenzonitrile (1.2mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were added successively at roomtemperature and the reaction mixture was allowed to stir at RT for 12 h. Water (10 mL) wasadded to the reaction mixture and the organic layer was extracted with ethyl acetate (2 x 20mL). The combined organic phases were washed with brine and dried over sodium sulfate. Thesolvent was removed and the residue was purified by column chromatography on silica gelusing hexanes / ethyl acetate as an eluent.Accordingly, the present invention provides quinazolinone compounds as potentiators ofrifampicin in MDR-TB isolates. The use of this synergistic drug in combination with anti-TBdrug like rifampicin, gives the opportunity to lower the MIC of the drug. The synthetic methodof quinazolinone analogues synthesis has been achieved using readily available 2-fluorobenzonitrile and 2-aminopyridine as starting materials. In summary, the present inventionprovides a transition-metal free synthetic protocol for the direct synthesis of quinazolinonemoiety from 2-aminopyridine and 2-fluorobenzonitrile by simple treatment with KtOBu.ExamplesThe following examples are given by way of illustration and therefore should not be construedto limit the scope of present invention.Example 1In an embodiment of the present invention, quinazolinone compounds 3a to3p are prepared asfollows.a) 11H-Pyrido[2,1-b]quinazolin-11-one; 3aAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Aminopyridine (1 mmol, 1 euiv), 2-fluorobenzonitrile (1.2mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were added successively at roomtemperature and the reaction mixture was allowed to stir at rt for 12 h. Water (10 mL) was addedto the reaction mixture and the organic layer was extracted with ethyl acetate (2 x 20 mL). Thecombined organic phases were washed with brine and dried over sodium sulfate. The solvent wasremoved and the residue was purified by column chromatography on silica gel usinghexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-aminopyridine (0.094g; 1 mmol), 2-fluorobenzonitrile (0.13 mL; 1.2 mmol), KtOBu (0.448 g; 4 mmol) in DMSO (5mL), quinazolinone 3a was obtained as yellow solid (0.136 g, 65% yield) after purification byflash chromatography using hexane / EtOAc (60:40) as the eluent; 1H NMR (500 MHz, CDCl3):δ 8.87 (d, J=7.3 Hz, 1H), 8.44 (dd, J1=1.4 Hz, J2=8.1 Hz, 1H), 7.76-7.86 (m, 2H), 7.45-7.56 (m,3H), 6.87 (m, 1H); 13C NMR (126 MHz, CDCl3): δ 158.9, 148.3, 147.7, 135.2, 134.3, 127.3,126.7, 126.6, 126.1, 125.2, 116.2, 112.6; IR (CHCl3):2924, 2855, 1716, 1644, 1610, 1557, 1531,1457, 1350, 1214, 1135, 1073, 761 cm-1; HRMS (+ESI)Calcd for C12H9N2O [M+H]+:211.0871; found: 211.0837.b) 6-Methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3bAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Amino-3-methylpyridine (1 mmol, 1 euiv), 2-fluorobenzonitrile (1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at RT for 12 h.Water (10 mL) was added to the reaction mixture and the organic layer was extracted with ethylacetate (2 x 20 mL).The combined organic phases were washed with brine and dried over sodiumsulfate. The solvent was removed and the residue was purified by column chromatography onsilica gel using hexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-amino-3-methylpyridine (0.1 mL, 1 mmol), 2-fluorobenzonitrile (0.13 mL; 1.2 mmol), KtOBu (0.448 g;4 mmol) in DMSO (5 mL), quinazolinone 3b was obtained as yellow solid (0.122 g, 58% yield)after purification by flash chromatography using hexane / EtOAc (80:20) as the eluent; 1H NMR(500 MHz, CDCl3): δ 8.81 (d, J=7.4 Hz, 1H), 8.45 (d, J=8.2 Hz, 1H), 7.78-7.87 (m, 2H), 7.47(m, 1H), 7.38 (d, J=6.6 Hz, 1H), 6.78 (t, J=6.9 Hz, 1H), 2.61 (s, 3H); 13C NMR (126 MHz,CDCl3): δ 159.5, 148.2, 147.5, 134.7, 134.5, 132.2, 127.4, 127.2, 125.1, 124.8, 116.1, 112.1,18.6;IR (CHCl3):2924, 1716, 1644, 1609, 1531, 1457, 1457, 1349, 1163, 1027, 901, 761, 691,637cm-1; HRMS (+ESI)Calcd for C13H11N2O [M+H]+: 211.0871; found: 211.0873.c) 6,8-Difluoro-11H-pyrido[2,1-b]quinazolin-11-one; 3cAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Amino-3,5-difluoropyridine(1 mmol, 1 euiv), 2-fluorobenzonitrile (1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at RT for 12 h.Water (10 mL) was added to the reaction mixture and the organic layer was extracted with ethylacetate (2 x 20 mL).The combined organic phases were washed with brine and dried over sodiumsulfate. The solvent was removed and the residue was purified by column chromatography onsilica gel using hexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-amino-3,5-difluoropyridine (0.130 g; 1 mmol), 2-fluorobenzonitrile (0.13 mL; 1.2 mmol), KtOBu (0.448g; 4 mmol) in DMSO (5 mL), quinazolinone 3c was obtained as yellow solid (0.148 g, 64% yield)after purification by flash chromatography using hexane / EtOAc (20:80) as the eluent; mp115-117 oC; 1H NMR (500 MHz, CDCl3): δ 8.64 (d, J=8.3 Hz, 2H), 8.14 (d, J=2.4 HZ, 1H), 7.70 (d,J=7.8 HZ, 2H), 7.34-7.47 (m, 1H), 7.18 (t, J=7.6 Hz, 1H); 13C NMR (126 MHz, CDCl3): δ153.6(dd, J1=3.3 Hz, J2=253 Hz), 146.3 (dd, J1=6.1 Hz, J2=263.1 Hz), 142.3, 140.2 (dd, J1=1.5 Hz,J2=9.1 Hz), 133.8, 132.4, 129.2 (dd, J1=5.7 Hz, J2=24.1 Hz), 121.7, 118.3, 116.8, 111.8 (dd,J1=18.9 Hz, J2=23.7 Hz), 100.6; IR (CHCl3):2917, 2219, 1627, 1608, 1531, 1455, 1424, 1307,1280, 1114, 894, 749 cm-1; HRMS (+ESI) Calcd for C12H7F2N2O [M+H]+: 233.0526; found:233.0529.d) 2-Bromo-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3dAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-amino-3-methylpyridine (1 mmol, 1 euiv), 5-bromo-2-fluorobenzonitrile(1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at RT for 12 h.Water (10 mL) was added to the reaction mixture and the organic layer was extracted with ethylacetate (2 x 20 mL).The combined organic phases were washed with brine and dried over sodiumsulfate. The solvent was removed and the residue was purified by column chromatography onsilica gel using hexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-amino-3-methylpyridine (0.1 mL; 1 mmol), 5-bromo-2-fluorobenzonitrile(0.240 g; 1.2 mmol), KtOBu(0.448 g; 4 mmol) in DMSO (5 mL), quinazolinone 3d was obtained as yellow solid (0.160 g,56% yield) after purification by flash chromatography using hexane / EtOAc (60:40) as the eluent;mp139-140 oC; 1H NMR (500 MHz, CDCl3): δ 8.94 (d, J=7.4 Hz, 1H), 7.98 (d, J=2.0 HZ, 1H),7.69 (dd, J1=1.9 Hz, J2=8.6 Hz, 1H), 7.53 (d, J=8.7 HZ, 1H), 7.30 (d, J=6.5 Hz, 1H), 6.64 (t, J=7.0Hz, 1H), 2.47 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 155.2, 147.9, 143.5, 135.8, 133.6, 132.9,129.6, 126.5, 126.0, 117.3, 116.5, 111.2, 18.7; IR (CHCl3): 2920, 1729, 1529, 1465, 1371, 1243,1149, 1075, 774 cm-1; HRMS (+ESI) Calcd for C13H10BrN2O [M+H]+: 288.9977; found:289.9982.e) 2-Bromo-7-methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3eAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Amino-4-methylpyridine (1 mmol, 1 euiv), 5-bromo-2-fluorobenzonitrile(1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at rt for 12 h. Water(10 mL) was added to the reaction mixture and the organic layer was extracted with ethyl acetate(2 x 20 mL).The combined organic phases were washed with brine and dried over sodium sulfate.The solvent was removed and the residue was purified by column chromatography on silica gelusing hexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-amino-4-methylpyridine (0.108 g; 1 mmol), 5-bromo-2-fluorobenzonitrile (0.240 g; 1.2 mmol), KtOBu(0.448 g; 4mmol) in DMSO (5 mL), quinazolinone 3e was obtained as yellow solid (0.137 g, 48%yield) after purification by flash chromatography using hexane / EtOAc (60:40) as the eluent;mp185-186 oC; 1H NMR (500 MHz, CDCl3): δ 8.94 (d, J=7.6 Hz, 1H), 7.97 (d, J=2.1 HZ, 1H),7.67 (dd, J1=2.2 Hz, J2=8.8 Hz, 1H), 7.44 (d, J=8.7 HZ, 1H), 7.04 (s, 1H), 6.56 (dd, J1=1.9 Hz,J2=7.6 Hz, 1H), 2.35 (s, 3H); 13C NMR (126 MHz, CDCl3): δ154.6, 148.2, 146.4, 144.2, 136.0,128.8, 127.2, 126.6, 123.2, 116.8, 116.4, 114.6, 21.3; IR (CHCl3):2922, 1659, 1621, 1541, 1526,1463, 1356, 1251, 1150, 1076, 863, 775cm-1; HRMS (+ESI)Calcd for C13H10BrN2O [M+H]+:288.9977; found: 288.9983.f) Preparation of 3-Bromo-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3f :An oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Amino-3-methylpyridine (1 mmol, 1 euiv), 4-bromo-2-fluorobenzonitrile (1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at rt for 12 h. Water(10 mL) was added to the reaction mixture and the organic layer was extracted with ethyl acetate(2 x 20 mL).The combined organic phases were washed with brine and dried over sodium sulfate.The solvent was removed and the residue was purified by column chromatography on silica gelusing hexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-amino-3-methylpyridine (0.1 mL; 1 mmol), 4-bromo-2-fluorobenzonitrile (0.240 g; 1.2 mmol), KtOBu(0.448 g; 4 mmol) in DMSO (5 mL), quinazolinone 3f was obtained as yellow solid (0.154 g,54% yield) after purification by flash chromatography using hexane / EtOAc (60:40) as the eluent;mp141-142 oC; 1H NMR (500 MHz, CDCl3): δ 8.91 (d, J=7.4 Hz, 1H), 7.82 (d, J=1.7 HZ, 1H),7.69 (d, J=8.6 HZ, 1H), 7.38 (dd, J1=1.7 Hz, J2=8.6 Hz, 1H), 7.30 (d, J=6.5 Hz, 1H), 6.64 (t, J=7.0Hz, 1H), 2.44 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 155.9, 148.3, 145.6, 133.6, 133.2, 130.1,127.5, 127.3, 125.9, 125.4, 113.8, 111.3, 18.7 ; IR (CHCl3):1616, 1592, 1538, 1459, 1419, 1371,1232, 1147, 1124, 1073, 871, 775, 665 cm-1; HRMS (+ESI)Calcd for C13H10BrN2O [M+H]+:288.9977; found: 288.9981.g) 3-Chloro-11H-pyrido[2,1-b]quinazolin-11-one; 3gAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Aminopyridine (1 mmol, 1 euiv), 4-chloro-2-fluorobenzonitrile (1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at rt for 12 h. Water(10 mL) was added to the reaction mixture and the organic layer was extracted with ethyl acetate(2 x 20 mL).The combined organic phases were washed with brine and dried over sodium sulfate.The solvent was removed and the residue was purified by column chromatography on silica gelusing hexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-aminopyridine(0.094 g; 1 mmol), 4-chloro-2-fluorobenzonitrile (0.187 g; 1.2 mmol), KtOBu (0.448 g; 4 mmol)in DMSO (5 mL), quinazolinone 3g was obtained as yellow solid (0.123 g, 54% yield) afterpurification by flash chromatography using hexane / EtOAc (60:40) as the eluent; 1H NMR (500MHz, CDCl3): δ 9.03 (d, J=7.3 Hz, 1H), 7.79 (d, J=8.7 HZ, 1H), 7.57 (d, J=1.9 HZ, 1H), 7.39-7.46 (m, 1H), 7.21-7.29 (m, 2H), 6.71 (t, J= 6.9 HZ, 1H); 13C NMR (126 MHz, CDCl3): δ155.1,148.7, 145.8, 139.0, 134.9, 127.9, 126.4, 125.6, 125.5, 124.9, 113.7, 111.5; IR (CHCl3):1650,1628, 1597, 1547, 1536, 1463, 1421, 1238, 1147, 1095, 939, 869, 758cm-1; HRMS (+ESI) Calcdfor C12H8ClN2O [M+H]+: 231.0325; found: 231.0329.h) 3-Fluoro-11H-pyrido[2,1-b]quinazolin-11-one; 3hAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Aminopyridine (1 mmol, 1 euiv), 2,4-difluorobenzonitrile(1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were added successively atroom temperature and the reaction mixture was allowed to stir at rt for 12 h. Water (10 mL) wasadded to the reaction mixture and the organic layer was extracted with ethyl acetate (2 x 20mL).The combined organic phases were washed with brine and dried over sodium sulfate. Thesolvent was removed and the residue was purified by column chromatography on silica gel usinghexanes / ethyl acetate as an eluent. Using the general experimental procedure on 2-aminopyridine(0.094 g; 1 mmol), 2,4-difluorobenzonitrile(0.166g; 1.2mmol), KtOBu (0.448 g; 4 mmol) inDMSO (5 mL), quinazolinone 3h was obtained as yellow solid (0.117 g, 55% yield) afterpurification by flash chromatography using hexane / EtOAc (60:40) as the eluent; 1H NMR (500MHz, CDCl3): δ 9.05 (d, J=7.4 Hz, 1H), 7.88(dd, J1=5.8 Hz, J2=8.9 Hz, 1H), 7.40-7.45 (m, 1H),7.20- 7.25 (m, 2H), 7.02-7.08 (m, 1H), 6.70 (m, 1H); 13C NMR (126 MHz, CDCl3): δ 165.7 (d,J=252.7 Hz), 155.1, 148.7, 147.1 (d, J=13.0 Hz), 135.0, 128.0, 126.6 (d, J=10.6 Hz), 125.5, 113.4(d, J=24.2 Hz), 112.1, 111.8 (d, J=21.2 Hz), 111.5;IR (CHCl3):1626, 1610, 1574, 1538, 1475,1452, 1387, 1264, 1155, 1140, 1091, 986, 887, 809, 776, 754, 657 cm-1;HRMS (+ESI)Calcd forC12H8FN2O [M+H]+: 215.0621; found: 215.0632.i) 4-Chloro-11H-pyrido[2,1-b]quinazolin-11-one; 3iAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Aminopyridine (1 mmol, 1 euiv), 3-Chloro-2-fluorobenzonitrile (1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at RT for 12 h.Water (10 mL) was added to the reaction mixture and the organic layer was extracted with ethylacetate (2 x 20 mL). The combined organic phases were washed with brine and dried over sodiumsulfate. The solvent was removed and the residue was purified by column chromatography onsilica gel using hexanes / ethyl acetate as an eluent. Using the general experimental procedure on2-aminopyridine (0.094 g; 1 mmol), 3-Chloro-2-fluorobenzonitrile (0.13 mL; 1.2mmol), KtOBu(0.448 g; 4mmol) in DMSO (5 mL), quinazolinone 3i was obtained as yellow solid (0.140 g, 61%yield) after purification by flash chromatography using hexane / EtOAc (60:40) as the eluent;1HNMR (500 MHz, CDCl3): δ 9.04 (d, J=7.4 Hz, 1H), 7.80 (dd, J1=1.2 Hz, J2=8.2 Hz, 1H), 7.75(dd, J1=1.2 Hz, J2=7.7 Hz, 1H), 7.40-7.50 (m, 2H), 7.24 (t, J=7.8 HZ, 1H), 6.74 (m, 1H); 13CNMR (126 MHz, CDCl3): δ155.3, 148.5, 142.0, 134.9, 133.2, 131.3, 127.9, 126.4, 124.1, 122.8,116.8, 111.9; IR (CHCl3):1650, 1618, 1594, 1547, 1532, 1439, 1251, 1130, 1085, 932, 901, 752cm-1; HRMS (+ESI) Calcd for C12H8ClN2O [M+H]+: 231.0325; found: 231.0332.j) 4-Chloro-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3jAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Amino-3-methylpyridine(1 mmol, 1 euiv), 3-chloro-2-fluorobenzonitrile (1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at RT for 12 h.Water (10 mL) was added to the reaction mixture and the organic layer was extracted with ethylacetate (2 x 20 mL).The combined organic phases were washed with brine and dried over sodiumsulfate. The solvent was removed and the residue was purified by column chromatography onsilica gel using hexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-amino-3-methylpyridine(0.1 mL; 1 mmol), 3-chloro-2-fluorobenzonitrile (0.187 g; 1.2 mmol), KtOBu(0.448 g; 4 mmol) in DMSO (5 mL), quinazolinone 3j was obtained as yellow solid (0.146 g,60% yield) after purification by flash chromatography using hexane / EtOAc (60:40) as the eluent;mp141-143 oC; 1H NMR (500 MHz, CDCl3): δ 8.94 (d, J=7.5 Hz, 1H), 7.78 (d, J=8.1 HZ, 1H),7.74 (d, J=7.6 HZ, 1H), 7.33 (d, J=6.5 Hz, 1H), 7.23 (t, J=7.9 Hz, 1H), 6.65 (t, J= 7.0 HZ, 1H),2.55(s, 3H); 13C NMR (126 MHz, CDCl3): δ155.6, 147.7, 141.3, 134.2, 132.8, 132.7, 131.8, 125.7,123.8, 122.5, 116.3, 111.3, 18.2; IR (CHCl3):1748, 1645, 1616, 1548, 1538, 1440, 1261, 1249,1137, 1074, 770 cm-1; HRMS (+ESI)Calcd for C21H15O3 [M+H]+: 245.0482; found: 245.0489.k) 4-Chloro-7-methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3kAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Amino-4-methylpyridine (1 mmol, 1 euiv), 3-chloro-2-fluorobenzonitrile (1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at RT for 12 h.Water (10 mL) was added to the reaction mixture and the organic layer was extracted with ethylacetate (2 x 20 mL). The combined organic phases were washed with brine and dried over sodiumsulfate. The solvent was removed and the residue was purified by column chromatography onsilica gel using hexanes / ethyl acetate as an eluent. Using the general experimental procedure on2-amino-4-methylpyridine (0.108 g; 1 mmol), 3-chloro-2-fluorobenzonitrile (0.187 g; 1.2 mmol),KtOBu (0.448 g; 4 mmol) in DMSO (5 mL), quinazolinone 3k was obtained as yellow solid (0.126g, 52% yield) after purification by flash chromatography using hexane / EtOAc (60:40) as theeluent; mp154-156 oC; 1H NMR (500 MHz, CDCl3): δ 8.94 (d, J=7.5 Hz, 1H), 7.78 (d, J=8.2HZ, 1H), 7.72 (d, J=7.6 HZ, 1H), 7.14-7.35 (m, 2H), 6.60 (dd, J1=1.8 Hz, J2=7.5 Hz, 1H), 2.36 (s,3H); 13C NMR (126 MHz, CDCl3): δ155.2, 148.4, 146.6, 142.3, 132.9, 130.9, 127.1, 123.8,123.4, 122.7, 116.4, 114.8, 21.1; IR (CHCl3):1660, 1621, 1596, 1534, 1436, 1358, 1255, 1134,1091, 924, 751cm-1;HRMS (+ESI) Calcd for C13H10ClN2O [M+H]+: 245.0482; found:245.0492.l) 4,6-Dichloro-11H-pyrido[2,1-b]quinazolin-11-one; 3lAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-amino-3-chloropyridine(1 mmol, 1 euiv), 3-chloro-2-fluorobenzonitrile(1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at RT for 12 h.Water (10 mL) was added to the reaction mixture and the organic layer was extracted with ethylacetate (2 x 20 mL).The combined organic phases were washed with brine and dried over sodiumsulfate. The solvent was removed and the residue was purified by column chromatography onsilica gel using hexanes / ethyl acetate as an eluent. Using the general experimental procedure on2-amino-3-chloropyridine (0.128 g; 1 mmol), 3-chloro-2-fluorobenzonitrile (0.187 g; 1.2 mmol),KtOBu (0.448 g; 4 mmol) in DMSO (5 mL), quinazolinone 3l was obtained as yellow solid (0.163g, 62% yield) after purification by flash chromatography using hexane / EtOAc (60:40) as theeluent; mp169-170 oC; 1H NMR (500 MHz, CDCl3): δ 9.01(dd, J1=1.2 Hz, J2=7.4 Hz, 1H), 7.78(d, J=7.9 Hz, 2H), 7.65(dd, J1=1.4 Hz, J2=7.2 Hz, 1H), 7.31 (t, J=7.9 HZ, 1H), 6.67 (t, J=7.3 HZ,1H); 13C NMR (126 MHz, CDCl3): δ 155.4, 145.5, 140.9, 133.9, 133.4, 132.1, 127.1, 125.1,122.7, 117.5, 116.7, 110.4; IR (CHCl3):2921, 1733, 1615, 1552, 1528, 1464, 1440, 1255, 1139,1117, 1056, 895, 775, 740 cm-1;HRMS (+ESI) Calcd for C12H7Cl2N2O [M+H]+: 264.9935;found: 264.9942.m) 4-Chloro-8-fluoro-11H-pyrido[2,1-b]quinazolin-11-one; 3mAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Amino-5-fluoropyridine (1 mmol, 1 euiv), 2-fluoro-3-chlorobenzonitrile (1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at RT for 12 h.Water (10 mL) was added to the reaction mixture and the organic layer was extracted with ethylacetate (2 x 20 mL).The combined organic phases were washed with brine and dried over sodiumsulfate. The solvent was removed and the residue was purified by column chromatography onsilica gel using hexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-amino-5-fluoropyridine (0.130 g; 1 mmol), 2-fluoro-3-chlorobenzonitrile(0.187 g; 1.2 mmol), KtOBu(0.448 g; 4 mmol) in DMSO (5 mL), quinazolinone 3m was obtained as yellow solid (0.146 g,59% yield) after purification by flash chromatography using hexane / EtOAc (60:40) as the eluent;mp177-178 oC; 1H NMR (500 MHz, CDCl3): δ 9.01 (dd, J1=2.6 Hz, J2=5.6 Hz, 1H), 7.72-7.92(m, 2H), 7.38-7.54 (m, 2H), 7.29 (t, J=7.9 HZ, 1H); 13C NMR (126 MHz, CDCl3): δ154.7, 151.9(d, J=241 Hz), 146.5, 141.6, 133.2, 131.6, 128.3 (d, J=12.0 Hz), 128.2 (d, J1=7.3 Hz), 124.7,122.8, 116.0, 113.6 (d, J=42.5 Hz); IR (CHCl3):1629, 1596, 1541, 1473, 1428, 1251, 1127, 1064,969, 808, 768 cm-1;HRMS (+ESI) Calcd for C12H7ClFN2O [M+H]+: 249.0231; found:249.0238.n) 12-Chloro-8H-isoquinolino[1,2-b]quinazolin-8-one; 3nAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 1-Aminoisoquinoline (1 mmol, 1 euiv), 3-chloro-2-fluorobenzonitrile(1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at RT for 12 h.Water (10 mL) was added to the reaction mixture and the organic layer was extracted with ethylacetate (2 x 20 mL).The combined organic phases were washed with brine and dried over sodiumsulfate. The solvent was removed and the residue was purified by column chromatography onsilica gel using hexanes / ethyl acetate as an eluent. Using this experimental procedure on 1-aminoisoquinoline (0.144 g; 1 mmol), 3-chloro-2-fluorobenzonitrile (0.187 g; 1.2 mmol), KtOBu(0.448 g; 4 mmol) in DMSO (5 mL), quinazolinone 3n was obtained as yellow solid (0.136 g,49% yield) after purification by flash chromatography using hexane / EtOAc (60:40) as the eluent;mp195-196 oC; 1H NMR (500 MHz, CDCl3): δ 9.08 (d, J=7.9 Hz, 1H), 8.80 (d, J=7.8 HZ, 1H),7.54-7.58 (m, 5H), 7.28 (t, J=7.8 Hz, 1H), 6.94 (d, J=7.8 Hz, 1H); 13C NMR (126 MHz, CDCl3):δ 155.6, 146.7, 141.0, 133.3, 133.0, 132.3, 128.3, 127.7, 127.4, 126.1, 124.8, 123.1, 122.6, 118.2,112.2; IR (CHCl3):1645, 1619, 1593, 1550, 486, 1436, 1401, 1345, 1262, 1130, 915, cm-1;HRMS (+ESI)Calcd for C16H10ClN2O [M+H]+: 281.0482; found: 281.0495.o) 4-Fluoro-11H-pyrido[2,1-b]quinazolin-11-one; 3oAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Aminopyridine (1 mmol, 1 euiv), 2,3-difluorobenzonitrile(1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were added successively atroom temperature and the reaction mixture was allowed to stir at rt for 12 h. Water (10 mL) wasadded to the reaction mixture and the organic layer was extracted with ethyl acetate (2 x 20 mL).The combined organic phases were washed with brine and dried over sodium sulfate. The solventwas removed and the residue was purified by column chromatography on silica gel usinghexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-aminopyridine (0.094g; 1 mmol), 2,3-difluorobenzonitrile (0.13 mL g; 1.2 mmol), KtOBu (0.448 g; 4 mmol) in DMSO(5 mL), quinazolinone 3o was obtained as yellow solid (0.117 g, 55% yield) after purification byflash chromatography using hexane / EtOAc (60:40) as the eluent; 1H NMR (500 MHz, CDCl3):δ 8.89 (d, J=7.3 Hz, 1H), 8.23(dd, J1=0.7 Hz, J2=8.2 Hz, 1H), 7.55-7.70 (m, 3H), 7.38-7.45 (m,1H), 6.93-7.01 (m, 1H); 13C NMR (126 MHz, CDCl3): δ158.2, 156.5(d, J=254.8 Hz), 147.9,134.9, 126.7, 126.6, 138.5 (d, J=12.1 Hz), 124.7 (d, J=7.6 Hz), 122.8 (d, J=4.4 Hz), 117.8 (d,J=1.5 Hz), 119.6 (d, J=18.8 Hz), 113.3; IR (CHCl3):1687, 1646, 1616, 1570, 1532, 1544, 1487,1440, 1358, 1251, 1139, 754 cm-1; HRMS (+ESI)Calcd for C12H8FN2O [M+H]+: 215.0621;215.0632.p) Preparation of 4-Fluoro-7-methyl-11H-pyrido[2,1-b] quinazolin-11-one; 3pAn oven-dried round bottomed flask (50 mL capacity) equipped with a magnetic stir bar wasevacuated and purged with argon. 2-Amino-4-methylpyridine (1 mmol, 1 euiv), 2,3-difluorobenzonitrile (1.2 mmol, 1.2 euiv), KtOBu (4 mmol, 4 euiv) and DMSO (5 mL) were addedsuccessively at room temperature and the reaction mixture was allowed to stir at rt for 12 h. Water(10 mL) was added to the reaction mixture and the organic layer was extracted with ethyl acetate(2 x 20 mL).The combined organic phases were washed with brine and dried over sodium sulfate.The solvent was removed and the residue was purified by column chromatography on silica gelusing hexanes / ethyl acetate as an eluent. Using this experimental procedure on 2-amino-4-methylpyridine (0.130 g; 1 mmol), 2,3-difluorobenzonitrile (0.13 mL; 1.2 mmol), KtOBu (0.448g; 4 mmol) in DMSO (5 mL), quinazolinone 3p was obtained as yellow solid (0.121 g, 53% yield)after purification by flash chromatography using hexane / EtOAc (60:40) as the eluent; mp178-180 oC; 1H NMR (500 MHz, CDCl3): δ 8.97 (d, J=7.6 Hz, 1H), 7.65 (d, J=8.2 HZ, 1H), 7.33-7.40 (m, 1H), 7.18-7.26 (m, 2H), 6.59 (dd, J1=1.9 Hz, J2=7.6 Hz, 1H), 2.36 (s, 3H); 13C NMR(126 MHz, CDCl3): δ 157.0 (d, J=253.4 Hz), 154.9, 148.3, 146.5, 135.5 (d, J=12.5 Hz), 127.2,123.7, 123.4 (d, J=7.9 Hz), 119.4 (d, J=4.2 Hz), 117.7 (d, J=19.3 Hz), 117.1 (d, J=2.3 Hz), 114.7,21.3 ; IR (CHCl3): 1922, 1694, 1656, 1611, 1569, 1538, 1484, 1438, 1357, 1244, 1184, 1072,996, 790, 759, 710 cm-1; HRMS (+ESI) Calcd for C13H10FN2O [M+H]+: 229.0777; found:229.0788.In an embodiment the present invention provides quinazolinone compounds 3a to 3p for itsapplication as potentiator in MDR-TB isolates with rifampicin. The use of a synergistic drug incombination with anti-TB drug like rifampicin, gives the opportunity to lower the MIC of thedrug and allowing its repurposing against drug resistant strains.The compound 3f and 3p shows modulatory effect at 3.9 μg / mL on the MIC of rifampicin. TheMIC of rifampicin (0.28 μg / mL) was reduced up to 8-fold (0.03 μg / mL) in presence of at 3.9μg / mL 3f / 3p.The compounds 3f and 3p showed no cytotoxic effect on THP-1 macrophages.The compound 3f and 3p shows the ability to have a bacteriostatic effect on intracellular M.tuberculosis H37Rv at Rif (0.07 μg / mL) + 3f (3.9 μg / mL) and at Rif (0.03 μg / mL) + 3p (3.9μg / mL) up to 72 h post treatment whereas Rif (0.03 μg / mL) + 3p (7.8 μg / mL) and Rif (0.07μg / mL) + 3p (7.8 μg / mL) showed bacteriostatic effect on intracellular M. tuberculosis H37Rv48 h post treatment.In an embodiment of the present invention, the compound 3p shows reduction in the expression of rifampicin responsible efflux pump genes in M. smegmatis mc2155 that have over-expressed orthologues in clinically resistant M. tuberculosis.Cytotoxicity analysis of 3f and 3p on THP-1 cell line: The human promonocytic cell line THP-1 (American Type Culture Collection) was cultured in RPMI 1640 (Gibco Laboratories) medium supplemented with 10% fetal calf serum (FCS) (HyClone) and was maintained at 37°C in a humidified, 5% CO2 atmosphere. THP-1 cells were differentiated using 20 ng / ml of phorbol myristate acetate (PMA; Sigma) for a minimum of 20 h. Cell viability was assessed by the MTT assay. MTT (Sigma) was added to THP-1 macrophages at a final working concentration of 1 mg / ml. The cells were incubated for 1 h at 37°C and a 5% CO2 atmosphere. This was followed by addition of 100 μl dimethyl sulfoxide (DMSO) to the samples to dissolve the formazan crystals. Quantitation was done by measuring sample absorbance at a 560-nm wavelength.Both 3f and 3p supported 100% cell viability of THP-1 differentiated macrophages. Thus, 3f and 3p does not have any cytotoxicity effect on the human cell line (Figure1).Table 1: MIC and Modulation of 3f and 3p with RifampicinDrug effects in intracellular Mycobacteria determined by CFU count:In vitro M. tuberculosis infections:Single-cell bacterial suspensions were made by aspirating five times with a 23-gauge needle and then three times with a 26-gauge needle, followed by a third dispersion with a 30-gauge needle. Bacteria were quantified by measuring absorbance at a wavelength of 600 nm. Maintaining the MOI of 10, complete medium containing the necessary number of bacteria was added to PMA-differentiated THP-1 cells. The cells were washed twice with warm RPMI medium and treated with amikacin (200 g / ml) to isolate and destroy any extracellular bacteria after 4 h of infection. Total medium was applied to the cells after 2 hr of amikacin therapy. In the experiment, this was referred to as the 0-hr time point, which was 4 + 2 hr after M. tuberculosis was introduced.Treatment:The infected cells were treated with RIF (0.03 μg / ml, 0.07 μg / ml), 3f (3.9 μg / ml, 7.8 μg / ml), 3p (3.9 μg / ml, 7.8 μg / ml) and in combination of RIF and 3f / 3p for 72 hr. Four sets of 96 well plateswere incubated for each time point along with a control set without the infection and only the treatment. This control set allowed us to monitor the cell viability at the respective time points in order to confirm change in the bacterial CFU / Ml because of THP-1 macrophage death.Colony forming unit measurement assay:MB-7H9 medium containing 0.06 percent SDS was used to lyse the infected cells. Serial dilutions of this lysate were plated on MB-7H11 agar (Difco) with square petri plates supplemented with 10% OADC (Becton, Dickinson) and 0.5 percent glycerol. The plates were incubated at 37°C to allow bacterial growth, and counts were performed after 14 and 21 days.Mtb H37Rv infected macrophages when treated with a combination of Rifampicin and 3f showed bactericidal activity after 48h of the drug exposure (Figure 2), whereas when treated with a combination of rifampicin and 3p most effective log reduction (>3log (CFU / mL) was observed after 72 h (Figure 3) of drug exposure. Expectedly, when the rifampicin, 3f and 3p were used exclusively on Mtb H37Rv infected macrophages the efficiency of the drugs was less in comparison to when used in combination. Thus, it can be inferred that in presence of 3f / 3p the MIC of rifampicin is reduced up to 8-fold (0.03 μg / ml) thus increasing its efficacy at a low concentration.Table 2: Up Regulated EP genes in M. tuberculosis under rifampicin stress and their orthologues in M. smegmatisStudy of differential expression of rifampicin efflux pump genes under combination effects of anti-Tb drugs along with quinazolinone analogues in M. smegmatis:The M. smegmatis cells were grown till 0.7 OD600 and treatments were added and the cells were incubated for 4h. The cells were then harvested and lysed using lysis buffer from Rneasy Mini Kit Plus (QIAGEN Biotechnology, Valencia, CA, USA) and lysed using 0.1 mm silica / zirconia beads (Polylabo) using Qiagen Bead-beater (3 x {30 / s for 60 sec}). Total RNA was extracted in two time-independent experiments and purified using the Rneasy Mini Kit Plus (QIAGENBiotechnology, Valencia, CA, USA), following the manufacturer's instructions. Synthesis of the first cDNA was carried out by random primer total RNA using PrimeScript RT reagent Kit with Gdna Eraser, Takara. Quantitative PCR was performed using SYBR green PCR master mix (Applied Biosystems, Foster City, CA, USA). Melting curves were assessed; samples were run in triplicate and the sigA gene was used to normalize all reactions. A negative control was included in all experiments. A reference assay was conducted in the absence of any drug.In our study, we focused on five efflux pumps that were recorded to be overexpressed in clinical M. tuberculosis isolates that showed RIF resistance. The five efflux pumps were selected due to the presence of their orthologues in M. smegmatis. Since M. tuberculosis is a slow-growing bacterium, finding new anti-tuberculosis drugs takes a long time. Another impediment to the production of TB drugs is the necessity of a biosafety level 3 (BSL-3) facilities for conducting Mtb-related study. Thus, the use of a non-pathogenic M. smegmatis in a preliminary screening of library molecules and iterative medicinal chemistry could make TB drug development more effective.At 16 μg / ml of RIF MSMEG_3069 showed highest level of expression followed by MSMEG_3815, MSMEG_5008, MSMEG_2380 and MSMEG_3119. When a combination of 16 μg / ml RIF + 6.25 μg / ml 3f and 16 μg / ml RIF + 6.25 μg / ml 3p was given to M. smegmatis the expression of MSMEG_3069 and MSMEG_3815 was reduced (Figure 4). Both these pumps were the highest expressed efflux proteins under 16 μg / ml RIF and both belong to the MFS super family. MSMEG_3815 was the only EP out of the five that were considered in our study that showed significant over expression in presence of 4 μg / ml RIF. On giving a combined treatment of 4 μg / ml RIF + 6.25 μg / ml 3p the expression was significantly reduced (Figure 5). 3p showed the most significant effect on the EP expression level at 4 μg / ml RIF treated M. smegmatis in comparison to 6.25 μg / ml 3f. Comparing the concentration dependent expression data, we concluded that 3p was effective in both the cases of RIF stress.Example 2Preparation of the synergistic compositionThe compositions comprising the quinazolinone compounds and rifampicin are prepared with amounts as specified in the below mentioned examples. The formulation may be administered as an oral suspension, capsule or in tablet form with excipients selected from methyl-p-hydroxybenzoate (E218), propyl-p-hydroxybenzoate (E216), potassium sorbate, sodium metabisulphite (E223), tween 80, diethanolamine, purified water, magnesium stearate, erytrosine, indigotine, sodium formaldehyde sulfoxylate, Ascorbic Acid, lactose monohydrate, talc, magnesium stearate, calcium stearate, lactose, titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172), iron oxide black (E172), gelatin, shellac glaze, propylene glycol (E1520) and ammonium hydroxide (E527) depending upon the dosage form.Example 2.1Components Amounts11H-Pyrido[2,1-b]quinazolin-11-one; 3a 7.8 μg / mLRifampicin 0.03 μg / mLExample 2.2Components Amounts6-Methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3b 31.2 μg / mLRifampicin 0.01 μg / mLExample 2.3Components Amounts6,8-Difluoro-11H-pyrido[2,1-b]quinazolin-11-one; 3c 62.5 μg / mLRifampicin 0.01 μg / mLExample 2.4Components Amounts2-Bromo-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3d 7.8 μg / mLRifampicin 0.03 μg / mLExample 2.5 Components Amounts3-Bromo-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3f : 3.9 μg / mLRifampicin 0.03 μg / mLExample 2.6Components Amounts3-Chloro-11H-pyrido[2,1-b]quinazolin-11-one; 3g 15.6 μg / mLRifampicin 0.01 μg / mLExample 2.7Components Amounts4-Chloro-7-methyl-11H-pyrido[2,1-b]quinazolin-11-one; 3k 7.8 μg / mLRifampicin 0.03 μg / mLExample 2.8Components Amounts4,6-Dichloro-11H-pyrido[2,1-b]quinazolin-11-one; 3l 15.6 μg / mLRifampicin 0.01 μg / mLExample 2.9Components Amounts4-Fluoro-7-methyl-11H-pyrido[2,1-b] quinazolin-11-one; 3p 3.9 μg / mLRifampicin 0.03 μg / mLExample 3The modulatory effect of 11H-pyrido[2,1-b]quinazolin-11-one compounds 3f and 3ponRifampicin MIC.3f and 3p were tested to determine their nature of interaction (synergy, antagonism or nointeraction) with rifampicin. Modulation assay was done by plating 2-fold dilution of rifampicin combined with the 2-fold dilution of 3f / 3p. 3f and 3p were tested at their sub-inhibitory concentration in combination with rifampicin.3f and 3p stocks were made indimethyl sulfoxide (DMSO) and working dilution was prepared in 7H9 broth. Similarly, the stock of 10mg / Ml fo rrifampicin was prepared in methanol and a subsequent1mg / mLworking solution was achieved by diluting in autoclaved double distilled water. M. tuberculosis H37Rv culture single-cell suspensions were prepared by aspiration five times each with a 23-and then a 26-gauge needle, followed by an additional dispersion for 3 times through a 30-gauge needle. Quantitation of bacteria was done by measuring absorbance at a 600-nm wavelength. The 96-well plate was inoculated with 2x105 cells / well of mid-log phase M. tuberculosis H37Rvculture and incubated at 37ºC for 7 days. The presence of bacterial growth was confirmed by adding alamar blue and incubating the plate at37ºC overnight. Modulation factor was calculated by dividing the MIC of the substrate (i.e., rifampicin) with the MIC in presence of both the substrate and the modulator. Fractional Inhibitory Concentration Index (FICI) was calculated by the following equation:FICI=FIC(A)+FIC(B)Where, FIC(A)= MIC (A in presence of B) / MIC of A aloneFIC(B)=MIC(BinpresenceofA) / MICofBaloneThe results were interpreted as follows: FICI≤0.5 shows synergistic activity, FICI≥4.0 shows antagonistic activity and 4.0>FICI>0.5 indicates no interaction (Table 1). The experiments were performed in triplicates and proper controls were maintained.Cytotoxicity assay of 3f and 3p on THP-1 macrophages. The human promonocytic cell line THP-1 (American Type Culture Collection) was cultured in RPMI 1640 (Gibco Laboratories) medium supplemented with 10% fetal calf serum (FCS)(HyClone)and was maintained at 37°C in a humidified, 5%CO2 atmosphere. THP-1cells were differentiated using 20ng / ml of phorbolmyristateacetate (PMA;Sigma) for a minimum of 20h. MTT cell viability assay.Cell viability was assessed by the MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide] assay. MTT (Sigma) was added to THP-1 macrophages at a final working concentration of 1mg / ml. The cells were incubated for 1h at 37°C and a 5% CO2 atmosphere. This was followed by addition of 100μL dimethyl sulfoxide DMSO to the samples to dissolve the formazan crystals. Quantitation was done by measuring sample absorbance at a 560-nmwavelength.Both 3f and 3p showed no cytotoxic effect on the THP-1 differentiated macrophages (Figure1) at 3.9 μg / mL and 7.8 μg / mL.Analysis of 3f and 3p efficacy in combination with rifampicin on Mtb H37Rv infected macrophagesIn vitro Mycobacterium tuberculosis infections.Single-cell bacterial suspensions were prepared by aspiration five times each with a 23- and then a 26-gauge needle, followed by an additional dispersion for 3 times through a 30-gauge needle. Quantitation of bacteria was done by measuring absorbance at a 600-nm wavelength (0.6 optical density [OD] value corresponds to ~106 bacteria). Complete medium containing the required number of bacteria was added to the PMA-differentiated THP-1 cells at a Multiplicity Of Infection (MOI) of 10. After 4 h of infection, the cells were washed twice with warm RPMI medium and treated with amikacin (200 g / ml) to remove and kill any extracellular bacteria. After 2 h of amikacin treatment, complete medium was added to the cells. This was referred to as the 0-h time point in the experiments, i.e., 4 + 2 h post-M. tuberculosis addition.Treatment.The infected cells were treated with rifampicin (0.03 μg / ml, 0.07 μg / ml), 3f (3.9 μg / ml, 7.8 μg / ml), 3p (3.9 μg / ml, 7.8 μg / ml) and in combination of rifampicin and 3f / 3p for 72 h.Colony forming unit measurement assay: 7H9 medium containing 0.06 percent SDS was usedto lyse the infected cells. Serial dilutions of this lysate were plated on 7H11 agar (Difco) with square petri plates supplemented with 10% OADC (Becton, Dickinson) and 0.5 percent glycerol. The plates were incubated at 37°C to allow bacterial growth, and counts were performed after 14 and 21 days.MTT cellviability assay. Cell viability was assessed by the MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assay. MTT (Sigma) was added to THP-1macrophages at a final working concentration of 1mg / ml. The cells were incubated for 1h at 37°C and a 5% CO2 atmosphere. This was followed by addition of 100μL dimethyl sulfoxide DMSO to the samples to dissolve the formazan crystals. Quantitation was done by measuring sample absorbance at a 560-nm wavelength.Mtb H37Rv infected macrophages when treated with a combination of Rifampicin and 3f showed bactericidal activity after 48 h of the drug exposure (Figure 2), whereas when treated with a combination of rifampicin and 3p most effective log reduction (>3 log (CFU / mL) was observed after 72 h (Figure 3) of drug exposure. Expectedly, when the rifampicin, 3f and 3p were used exclusively on Mtb H37Rv infected macrophages the efficiency of the drugs was less in comparison to when used in combination. Thus, it can be inferred that in presence of 3f / 3p the MIC of rifampicin is reduced up to 8-fold (0.03 μg / ml) thus increasing its efficacy at a low concentration.Differential expression of efflux pump genes on treatment with Rifampicin Due to the slow growing nature of M. tuberculosis, we opted to the molecular analysis of the combination treatment of rifampicin and 3f / 3p on M. smegmatis. The orthologues of the efflux pumps that have been found to be overexpressed in M. tuberculosis rifampicin resistant strain was determined in M. smegmatis with the help of Mycobrowser. This gave us five efflux pump genes (Table 2) in M. smegmatis to study their expression level under combination treatment of rifampicin and 3f / 3p (Figure 4 and 5).The M. smegmatis cells were grown till 0.7 OD600 and treatments were added and the cells were incubated for 4h. The cells were then harvested and lysed using lysis buffer from RNeasy Mini Kit Plus (QIAGEN Biotechnology, Valencia, CA, USA) and bead beating. Total RNA was extracted in two time-independent experiments and purified using the RNeasy Mini Kit Plus (QIAGEN Biotechnology, Valencia, CA, USA), following the manufacturer's instructions. Synthesis of the first cDNA was carried out by random primer total RNA using Prime Script RT reagent Kit with g-DNA Eraser, Takara. Quantitative PCR was performed using SYBR green PCR master mix (Applied Biosystems, Foster City, CA, USA).Melting curves were assessed; samples were run in triplicate and the sigA gene was used to normalize all reactions. A negative control was included in all experiments. A reference assay was conducted in the absence of any drug.In our study we focused on five efflux pumps that were recorded to be overexpressed in clinical M. tuberculosis isolates that showed RIF resistance. The five efflux pumps were selected due tothe presence of their orthologues in M. smegmatis. Since M. tuberculosis is a slow-growing bacterium, finding new anti-tuberculosis drugs takes a long time. Another impediment to the production of TB drugs is the necessity of a biosafety level 3 (BSL-3) facilities for conducting Mtb-related study. Thus, the use of a non-pathogenic M. smegmatis in a preliminary screening of library molecules and iterative medicinal chemistry could make TB drug development more effective.At 16 μg / ml of RIF MSMEG_3069 showed highest level of expression followed by MSMEG_3815, MSMEG_5008, MSMEG_2380 and MSMEG_3119. When a combination of 16 μg / ml RIF + 6.25 μg / ml 3f and 16 μg / ml RIF + 6.25 μg / ml 3p was given to M. smegmatis the expression of MSMEG_3069 and MSMEG_3815 was reduced (Figure 4). Both these pumps were the highest expressed efflux proteins under 16 μg / ml RIF and both belong to the MFS super family.MSMEG_3815 was the only EP out of the five that were considered in our study that showed significant over expression in presence of 4 μg / ml RIF. On giving a combined treatment of 4 μg / ml RIF + 6.25 μg / ml 3p the expression was significantly reduced (Figure 5). 3p showed the most significant effect on the EP expression level at 4 μg / ml RIF treated M. smegmatis in comparison to 6.25 μg / ml 3f. Comparing the concentration dependent expression data, we concluded that 3p was effective in both the cases of RIF stress.Advantages:The compounds 3f and 3p are rifampicin efflux pump inhibitors that showed the capability to reduce the MIC in M. tuberculosis. The compounds show excellent activity to inhibit intracellular bacterial growth of M. tuberculosis. Also, the ability to reduce the expression of efflux pumps MSMEG_3069, MSMEG_3815 and MSMEG_5008 paves the path for its ability to do the same in the M. tuberculosis orthologues of the same.

Claims

1. A synergistic composition to potentiate the efficacy of rifampicin against Mycobacterium tuberculosis comprising: a. a quinazolinone compounds of Formula I wherein R1 is selected from the group consisting of H, Br, Cl and F and R2 is selected from the group consisting of H, Cl, F and Me and b. rifampicin, wherein the ratio of compounds of Formula I to rifampicin is 1:0.007.

2. The composition as claimed in claim 1, wherein R1 is selected from Br and F and R2 is Me.

3. The composition as claimed in claim 1, wherein the compound of Formula I is selected from the group consisting of: 11H-Pyrido[2,1-b]quinazolin-11-one, 6-Methyl-11H-pyrido[2,1-b]quinazolin-11-one, 6,8-Difluoro-11H-pyrido[2,1-b]quinazolin-11-one, 2-Bromo-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one, 2-Bromo-7-methyl-11H-pyrido[2,1-b]quinazolin-11-one, 3-Bromo-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one, 3-Chloro-11H-pyrido[2,1-b]quinazolin-11-one, 3-Fluoro-11H-pyrido[2,1-b]quinazolin-11-one, 4-Chloro-11H-pyrido[2,1-b]quinazolin-11-one, 4-Chloro-6-methyl-11H-pyrido[2,1-b]quinazolin-11-one, 4-Chloro-7-methyl-11H-pyrido[2,1-b]quinazolin-11-one, 4,6-Dichloro-11H-pyrido[2,1-b]quinazolin-11-one, 4-Chloro-8-fluoro-11H-pyrido[2,1-b]quinazolin-11-one, 12-Chloro-8H-isoquinolino[1,2-b]quinazolin-8-one, 4-Fluoro-11H-pyrido[2,1-b]quinazolin-11-one and 4-Fluoro-7-methyl-11H-pyrido[2,1-b] quinazolin-11-one.

4. The composition as claimed in claim 1, wherein the compounds of Formula I is 3-Bromo- 6-methyl-11H-pyrido[2,1-b]quinazolin-11-one.

5. The composition as claimed in claim 1, wherein the compounds of Formula I is4-Fluoro-7-methyl-11H-pyrido[2,1-b]quinazolin-11-one.

6. The composition as claimed in claim 1, wherein the composition is in the form of an oral suspension, capsule or tablet with excipients selected from the group consisting of methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, potassium sorbate, sodium metabisulphite, tween 80, diethanolamine, purified water, magnesium stearate, erytrosine, indigotine, sodium formaldehyde sulfoxylate, Ascorbic Acid, lactose monohydrate, talc, magnesium stearate, calcium stearate, lactose, titanium dioxide, iron oxide red, iron oxide yellow, iron oxide black, gelatin, shellac glaze, propylene glycol and ammonium hydroxide.

7. The composition as claimed in claim 1, wherein the compounds of Formula I acts as a rifampicin efflux pump inhibitor in M. tuberculosis.

8. The composition as claimed in claim 1, wherein the MIC of rifampicin is reduced by 8-folds.

9. The composition as claimed in claim 1, wherein the synergistic bactericidal activity is exhibited within 48 h to 72 h.

10. A process for preparing a synergistic composition to potentiate the efficacy of rifampicin against M. tuberculosis comprising mixing; (a) a quinazolinone compounds of Formula I wherein R1 is selected from the group consisting of H, Br, Cl and F and R2 is selected from the group consisting of H, Cl, F and Me and and (b) rifampicin, at a ratio of 1:0.007.